74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
C Collegium Pharmaceutical Inc
C
Closed
SectorHealthcare
26.84 3.35
Overview
Share price change
24h
Min
25.85
Max
26.92
Income | 3.2M 13M |
|---|---|
Sales | 23M 182M |
P/E Sector Avg | 14.468 57.333 |
EPS | 1.77 |
Profit margin | 6.89 |
Employees | 357 |
EBITDA | -38M 38M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +60.57% upside |
Next Earnings | 8 May 2025 |
|---|
Market Cap | -74M 868M |
|---|---|
Previous open | 23.49 |
Previous close | 26.84 |
Technical Score
By Trading Central
Confidence
Bullish Evidence
Collegium Pharmaceutical Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Collegium Pharmaceutical Inc Forecast
Price Target
By TipRanks
60.57% upside
12 Months Forecast
Average 43 USD 60.57%
High 50 USD
Low 36 USD
Based on 5 Wall Street analysts offering 12 month price targets forCollegium Pharmaceutical Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Collegium Pharmaceutical Inc
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
